197 related articles for article (PubMed ID: 28537897)
1. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Lwin TM; Hwang HK; Delong JC; Clary BM; Bouvet M; Unno M; Hoffman RM
Oncotarget; 2017 Jul; 8(29):47490-47496. PubMed ID: 28537897
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
4. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961
[TBL] [Abstract][Full Text] [Related]
6. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
9. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Nelson SD; Dry SM; Li Y; Russell TA; Singh AS; Chmielowski B; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(11):1063-1069. PubMed ID: 28426279
[TBL] [Abstract][Full Text] [Related]
10. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.
Adelmann CH; Truong KA; Liang RJ; Bansal V; Gandee L; Saporito RC; Lee W; Du L; Nicholas C; Napoli M; Mino B; South AP; Proby CM; Leigh IM; Coarfa C; Flores ER; Tsai KY
J Invest Dermatol; 2016 Sep; 136(9):1920-1924. PubMed ID: 27293029
[No Abstract] [Full Text] [Related]
11. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
12. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
13. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
[TBL] [Abstract][Full Text] [Related]
14. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis.
Newhook TE; Lindberg JM; Adair SJ; Kim AJ; Stelow EB; Rahma OE; Parsons JT; Bauer TW
Ann Surg Oncol; 2016 Jun; 23(6):1993-2000. PubMed ID: 26847682
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX).
Hiroshima Y; Zhao M; Maawy A; Zhang Y; Katz MH; Fleming JB; Uehara F; Miwa S; Yano S; Momiyama M; Suetsugu A; Chishima T; Tanaka K; Bouvet M; Endo I; Hoffman RM
J Cell Biochem; 2014 Jul; 115(7):1254-61. PubMed ID: 24435915
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
18.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
19. High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Sep; 118(9):2739-2743. PubMed ID: 28176365
[TBL] [Abstract][Full Text] [Related]
20. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
